Stockscreener 앱 받기
1.70
2.30%
-0.04
시간 외 거래:
1.68
-0.02
-1.18%
전일 마감가:
$1.74
열려 있는:
$1.69
하루 거래량:
68,994
Relative Volume:
0.22
시가총액:
$11.96M
수익:
-
순이익/손실:
$-7.72M
주가수익비율:
-0.6441
EPS:
-2.6394
순현금흐름:
$-6.25M
1주 성능:
-21.30%
1개월 성능:
-33.59%
6개월 성능:
-28.69%
1년 성능:
-33.85%
1일 변동 폭
$1.655
$1.77
1주일 범위
$1.655
$2.18
52주 변동 폭
$1.55
$4.4899
에데사 바이오테크 Stock (EDSA) Company Profile
명칭
Edesa Biotech Inc
전화
(905) 475-1234
주소
100 SPY COURT, MARKHAM, ON
EDSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.70 | 12.77M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
에데사 바이오테크 주식(EDSA)의 최신 뉴스
Edesa Biotech (NASDAQ:EDSA) Given “Buy” Rating at HC Wainwright - Defense World
HC Wainwright & Co. Reiterates Edesa Biotech (EDSA) Buy Recommendation - Nasdaq
Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus
Is Edesa Biotech Inc. stock affected by interest rate hikesWeekly Volume Report & Risk Managed Investment Strategies - newser.com
Is Edesa Biotech Inc. still worth holding after the dipPortfolio Gains Report & Community Driven Trade Alerts - newser.com
Has Edesa Biotech Inc. found a price floorWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Edesa Biotech Inc. stock2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Edesa Biotech, Inc. (EDSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Edesa Biotech to Participate in Key Industry Conferences - TipRanks
Edesa Biotech Announces Upcoming Conference Schedule - The Manila Times
Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan
Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st
Will Edesa Biotech Inc. stock benefit from sector rotationQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Edesa Biotech Inc a good long term investmentMean Reversion Trades & Affordable Trading Portfolio - earlytimes.in
Edesa Biotech reports positive Phase III results for ARDS treatment - Yahoo
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial - Investing.com Canada
EDSA’s Market Surge: Time to Jump In? - StocksToTrade
Edesa Biotech (EDSA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial By Investing.com - Investing.com South Africa
EDSA’s Performance: What’s Driving the Change? - timothysykes.com
Edesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS - Nasdaq
Edesa Biotech reports positive Phase 3 results for ARDS drug candidate - Investing.com Nigeria
Edesa Biotech Announces Positive Phase 3 Study Results - TipRanks
Edesa Biotech Announces Positive Phase 3 Results for ARDS Treatment - TradingView
Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative
[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - GlobeNewswire
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
에데사 바이오테크 (EDSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):